US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gyre Therapeutics

7.42

+0.04000.54%

Post-market: 7.440.0200+0.27%18:08 EDT

Volume:1.05M

Turnover:7.80M

Market Cap:712.17M

PE:154.34

High:7.60

Open:7.38

Low:7.20

Close:7.38

Loading ...

Overview Company News Filings

Stifel Nicolaus Initiates a Buy Rating on Gyre Therapeutics (GYRE)

Innovative Strategy and Strong Pipeline Position Gyre Therapeutics for Market Success

GNI's Gyre Therapeutics Begins Phase 1 Dosing of PAH Drug F230 in China

MT Newswires Live

GNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in China

Gyre Therapeutics announces first doing in Phase 1 trial of F230

Gyre Therapeutics Initiates Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

Gyre Therapeutics Inc - F230 Nda Submission to Nmpa Planned for Q3 2025

THOMSON REUTERS

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

THOMSON REUTERS

Gyre Therapeutics Inc. Conducted Annual Stockholders Meeting

GNI Group Says Gyre Therapeutics Completes $23 Million Public Offering

MT Newswires Live

Gyre Therapeutics Inc. President and Director, Songjiang Ma, Reports Disposal of Common Shares

Press Release: Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Gyre Therapeutics President Ma Songjiang Reports Disposal of Common Shares

Gyre Therapeutics Up Nearly 24%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk

Gyre Therapeutics Announces Stock Offering Agreement

BUZZ-U.S. STOCKS ON THE MOVE-Delcath Systems, Seagate, Perpetua Resources

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday After Trump Proposes EU Tariffs

MT Newswires Live

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Gold miners, Intuit

BUZZ-Gyre Therapeutics tumbles after equity raise

Gyre Therapeutics Prices $20 Million Common Stock Offering

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GYRE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":7.42,"timestamp":1751054400000,"preClose":7.38,"halted":0,"volume":1052009,"hourTrading":{"tag":"盘后","latestPrice":7.44,"preClose":7.42,"latestTime":"18:08 EDT","volume":397817,"amount":2951769.223362,"timestamp":1751062080619},"delay":0,"floatShares":25607700,"shares":95979800,"eps":0.048077,"marketStatus":"Market Closed","change":0.04,"latestTime":"06-27 16:00:00 EDT","open":7.38,"high":7.5973,"low":7.2,"amount":7800734.472550601,"amplitude":0.053835,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.048077,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":7.38,"postHourTrading":{"tag":"盘后","latestPrice":7.44,"preClose":7.42,"latestTime":"18:08 EDT","volume":397817,"amount":2951769.223362,"timestamp":1751062080619},"volumeRatio":5.623090823505809,"impliedVol":0.938,"impliedVolPercentile":0.7273},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":25607700,"roa":"5.18%","roe":"12.12%","lyrEps":0.142017,"volumeRatio":5.623090823505809,"shares":95979800,"dividePrice":0,"high":7.5973,"amplitude":0.053835,"preClose":7.38,"low":7.2,"week52Low":6.11,"pbRate":"10.45","psRate":"7.08","week52High":19,"institutionHeld":0.0832,"latestPrice":7.42,"eps":0.048077,"divideRate":0,"volume":1052009,"delay":0,"ttmEps":0.048077,"open":7.38,"prevYearClose":12.1,"prevWeekClose":8.07,"prevMonthClose":9.07,"prevQuarterClose":7.72,"fiveDayClose":8.07,"twentyDayClose":9.46,"sixtyDayClose":6.41},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546251512","title":"Stifel Nicolaus Initiates a Buy Rating on Gyre Therapeutics (GYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2546251512","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546251512?lang=en_us&edition=fundamental","pubTime":"2025-06-25 07:25","pubTimestamp":1750807505,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE – Research Report) received a Buy rating and a $28.00 price target from Stifel Nicolaus analyst Stephen Willey today. The c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-initiates-a-buy-rating-on-gyre-therapeutics-gyre-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-initiates-a-buy-rating-on-gyre-therapeutics-gyre-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","SF"],"gpt_icon":0},{"id":"2544975042","title":"Innovative Strategy and Strong Pipeline Position Gyre Therapeutics for Market Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2544975042","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544975042?lang=en_us&edition=fundamental","pubTime":"2025-06-18 18:17","pubTimestamp":1750241829,"startTime":"0","endTime":"0","summary":"Charles Zhu, an analyst from LifeSci Capital, has initiated a new Buy rating on Gyre Therapeutics (GYRE). Charles Zhu’s rating is based on several ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/innovative-strategy-and-strong-pipeline-position-gyre-therapeutics-for-market-success-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/innovative-strategy-and-strong-pipeline-position-gyre-therapeutics-for-market-success-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4595","BK4600","GYRE","BK4596","STRK","BK4139","BK4516","BK4588","BK4023","BK4585"],"gpt_icon":0},{"id":"2542659665","title":"GNI's Gyre Therapeutics Begins Phase 1 Dosing of PAH Drug F230 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2542659665","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542659665?lang=en_us&edition=fundamental","pubTime":"2025-06-12 12:00","pubTimestamp":1749700840,"startTime":"0","endTime":"0","summary":"GNI Group  said its subsidiary Gyre Therapeutics has begun dosing in a Phase 1 trial of F230, a treatment candidate for pulmonary arterial hypertension , in China, according to a Wednesday filing on the Tokyo Stock Exchange.F230, a selective endothelin A receptor antagonist originally developed by Eisai, was licensed to GNI in 2020. The trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers.GNI said the move expands Gyre's fibrosis-focused pipeline, which includes lead drug Hydronidone, into cardiovascular disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2542327687","title":"GNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2542327687","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542327687?lang=en_us&edition=fundamental","pubTime":"2025-06-11 09:22","pubTimestamp":1749604945,"startTime":"0","endTime":"0","summary":"GNI Group ( ($JP:2160) ) has shared an announcement. GNI Group’s subsidiary, Gyre Therapeutics, has initiated a Phase 1 clinical trial in China for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gni-groups-gyre-therapeutics-begins-phase-1-trial-for-pah-drug-in-china?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gni-groups-gyre-therapeutics-begins-phase-1-trial-for-pah-drug-in-china?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2542319829","title":"Gyre Therapeutics announces first doing in Phase 1 trial of F230","url":"https://stock-news.laohu8.com/highlight/detail?id=2542319829","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542319829?lang=en_us&edition=fundamental","pubTime":"2025-06-10 19:10","pubTimestamp":1749553817,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endoth...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-first-doing-in-phase-1-trial-of-f230-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-first-doing-in-phase-1-trial-of-f230-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2542316534","title":"Gyre Therapeutics Initiates Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2542316534","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542316534?lang=en_us&edition=fundamental","pubTime":"2025-06-10 19:01","pubTimestamp":1749553271,"startTime":"0","endTime":"0","summary":"SAN DIEGO, June 10, 2025  -- Gyre Therapeutics , a commercial-stage biopharmaceutical company, has announced the commencement of a Phase 1 clinical trial for F230, targeting pulmonary arterial hypertension . The first volunteer has been successfully dosed in this trial, which aims to evaluate the safety, tolerability, and pharmacokinetics of F230 in healthy volunteers. This trial signifies Gyre's expansion into the PAH field, a condition with limited treatment options. F230, a novel endothelin A receptor antagonist, is designed to mitigate pulmonary vascular remodeling and reduce pulmonary pressure. Results from this Phase 1 trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. publish","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL3s6wtj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4139","GYRE","LU2210150020.SGD","BK4585","NDAQ","LU2210149790.SGD","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2542316306","title":"Gyre Therapeutics Inc - F230 Nda Submission to Nmpa Planned for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2542316306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542316306?lang=en_us&edition=fundamental","pubTime":"2025-06-10 19:00","pubTimestamp":1749553200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nTUA63B6KH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2542315718","title":"Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2542315718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542315718?lang=en_us&edition=fundamental","pubTime":"2025-06-10 19:00","pubTimestamp":1749553200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nTUA63B6KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2541985579","title":"Gyre Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541985579","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541985579?lang=en_us&edition=fundamental","pubTime":"2025-06-06 18:01","pubTimestamp":1749204095,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 4, 2025. During the meeting, all director nominees, including Gordon Carmichael, Ph.D., Songjiang Ma, and Ping Zhang, were elected. Additionally, the appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified. All proposals presented at the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDLLZPNb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2540750880","title":"GNI Group Says Gyre Therapeutics Completes $23 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2540750880","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540750880?lang=en_us&edition=fundamental","pubTime":"2025-06-02 14:08","pubTimestamp":1748844480,"startTime":"0","endTime":"0","summary":"GNI Group  said its core subsidiary, Gyre Therapeutics, completed a public offering of common stock, raising about $23 million in gross proceeds, according to a Monday filing on the Tokyo Stock Exchange.The offering closed on May 29, with Gyre issuing 2,555,555 shares at $9 apiece, including 333,333 shares from the underwriters' overallotment option, the filing said.GNI said its ownership in Gyre has decreased to 80.69% from 83.03%, though the unit remains a consolidated subsidiary of the company.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2539934562","title":"Gyre Therapeutics Inc. President and Director, Songjiang Ma, Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2539934562","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539934562?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:01","pubTimestamp":1748548902,"startTime":"0","endTime":"0","summary":"Songjiang Ma, President and Director of Gyre Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL6RglYg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gyre Therapeutics Inc. President and Director, Songjiang Ma, Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2539293488","title":"Press Release: Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2539293488","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539293488?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:01","pubTimestamp":1748548860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May 29, 2025  -- Gyre Therapeutics  , an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that it closed its previously announced underwritten public offering of 2,555,555 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 333,333 shares, at a public offering price of $9.00 per share, less the underwriting discount. The gross proceeds of the offering to Gyre, before deducting underwriting discounts and commissions and other offering expenses payable by Gyre, were approximately $23.0 million.Jefferies acted as lead book-running manager for the offering and H.C. Wainwright & Co. acted as co-manager for the offering.Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, includ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2538491961","title":"Gyre Therapeutics President Ma Songjiang Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2538491961","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538491961?lang=en_us&edition=fundamental","pubTime":"2025-05-28 04:02","pubTimestamp":1748376173,"startTime":"0","endTime":"0","summary":"Songjiang Ma, President and Director of Gyre Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL96wpty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gyre Therapeutics President Ma Songjiang Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2538460329","title":"Gyre Therapeutics Up Nearly 24%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2538460329","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538460329?lang=en_us&edition=fundamental","pubTime":"2025-05-27 22:46","pubTimestamp":1748357160,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc  is currently at $10.75, up $2.07 or 23.87%. --On pace for largest percent increase since Feb. 23, 2024, when it rose 37.69%. --Down 99.98% from its all-time closing high of $47155.54 on March 3, 2011. --Up 5.93% from 52 weeks ago , when it closed at $10.15. --Down 36% from its 52-week closing high of $16.80 on Nov. 11, 2024. --Up 67.73% from its 52-week closing low of $6.41 on April 1, 2025. --Traded as high as $11.61; highest intraday level since May 16, 2025, when it hit $11.67. --Up 33.76% at today's intraday high; largest intraday percent increase since Feb. 23, 2024, when it rose as much as 50.44%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2537157072","title":"Gyre Therapeutics Announces Stock Offering Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2537157072","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537157072?lang=en_us&edition=fundamental","pubTime":"2025-05-24 05:40","pubTimestamp":1748036423,"startTime":"0","endTime":"0","summary":"An announcement from Gyre Therapeutics ( ($GYRE) ) is now available. On May 22, 2025, Gyre Therapeutics, Inc. announced an underwriting agreement w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-announces-stock-offering-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-announces-stock-offering-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2537334159","title":"BUZZ-U.S. STOCKS ON THE MOVE-Delcath Systems, Seagate, Perpetua Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2537334159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537334159?lang=en_us&edition=fundamental","pubTime":"2025-05-24 01:58","pubTimestamp":1748023126,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Delcath Systems, Seagate, Perpetua ResourcesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nL6N3RV0K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863902.USD","LU2552382215.SGD","LU2361044865.SGD","GRDN","LU0306806265.USD","NEM","SCHW","LU0323239441.USD","GYRE","IE00B19Z9P08.USD","IVZ","LU1894683264.USD","LU0868494708.USD","IE00BFMHRM44.USD","GB00BDT5M118.USD","LU2168564065.EUR","ROST","STX","BAC","LU0444971666.USD","APO","LU0154236417.USD","IE00BDCRKT87.USD","LU0265550946.USD","LU1861559042.SGD","IE00BJJMRY28.SGD","CEG","MACW.SI","WDAY","DCTH","IE00BKDWB100.SGD","DECK","BAH","TSYW.SI","LU0724617625.USD","IE00BLSP4452.SGD","AAP","IE00B7KXQ091.USD","PPTA","BK4575","INTU","CPRT","KKR","HNRG","IE0008368304.USD"],"gpt_icon":1},{"id":"2537139479","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday After Trump Proposes EU Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2537139479","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537139479?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:43","pubTimestamp":1748004193,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 1.6% and the actively traded Invesco QQQ Trust (QQQ) was 2% lower in Friday's premarket activity after President Trump propo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SOXX","IYJ","XSD","FDN","IYH","IBB","XLY","HNRG","XLF","UNG","GYRE","RTH.AU","IYE","BAH.AU","FAS","VDC","PMR","XLP","INTU","BAH","IVV","USO","VHT.AU","XLE","SPY","IYK","FAZ","BITO","SLV",".SPX",".DJI","XRT","IPK","IGM","VHT","EQR","DB",".IXIC","EEM","EXI","IYW","SPY.AU","XLK","XLV","XLI","MNSO"],"gpt_icon":1},{"id":"2537359761","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Gold miners, Intuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2537359761","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537359761?lang=en_us&edition=fundamental","pubTime":"2025-05-23 19:43","pubTimestamp":1748000609,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Gold miners, IntuitEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nL6N3RV0I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2092937221.SGD","LU0971096721.USD","LU0820561909.HKD","LU2264538146.SGD","LU1121112475.USD","CPRT","LU2089284900.SGD","IE00BZ1G4Q59.USD","TSYW.SI","LU2360108059.USD","BK4017","LU0211326839.USD","LU1778281490.HKD","LU0426417589.USD","BK4592","TSLA","IE00BQXX3D17.EUR","GYRE","LU0157215616.USD","BK4527","LU0683600562.USD","LU2746668461.USD","LU1363072403.SGD","LU2471134952.CNY","LU0208291251.USD","LU1720051017.SGD","LU1066053197.SGD","LU0994945656.USD","NEM","DECK","LU2210150020.SGD","IE0008368304.USD","LU1914381329.SGD","LU0719512351.SGD","IE00BQXX3F31.USD","ROST","LU0011850046.USD","LU1861215975.USD","LU0061474960.USD","SG9999015945.SGD","INTU","BK4598","LU1119994496.HKD","LU2357305700.SGD","LU1023059493.AUD","LU2750360641.GBP","LU0070302665.USD","LU0330918003.SGD","IE00BN8TJ469.HKD","SG9999015952.SGD"],"gpt_icon":1},{"id":"2537388291","title":"BUZZ-Gyre Therapeutics tumbles after equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2537388291","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537388291?lang=en_us&edition=fundamental","pubTime":"2025-05-23 18:36","pubTimestamp":1747996592,"startTime":"0","endTime":"0","summary":"BUZZ-Gyre Therapeutics tumbles after equity raise**  Shares of Gyre Therapeutics GYRE.O down 15.3% before the bell to $9.50 after follow-on priced** San Diego-based biotech late Thurs announced ~2.2 mln shares at $9 for $20 mln gross proceeds** Offering price represents 19.7% discount to stock's last sale** Co intends to use net proceeds to fund advancement of its Phase II trial of F351 in metabolic dysfunction-associated steatohepatitis -associated liver fibrosis in the U.S., for R&D, and manufacturing among other purposes** Jefferies is bookrunner for offering** Late Thurs, co said its lead compound, Hydronidone , met primary endpoint in pivotal Phase III trial evaluating efficacy and safety for treatment of fibrosis in patients with chronic hepatitis B in China** With ~93.8 mln shares outstanding as of May 1, co has ~$1bln market cap** GYRE shares on Thurs rose 8.1% to $11.21, trimming YTD loss to ~7%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nL6N3RV0GO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","BK4127","BK4139","GYRE","JEF"],"gpt_icon":0},{"id":"2537886531","title":"Gyre Therapeutics Prices $20 Million Common Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2537886531","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537886531?lang=en_us&edition=fundamental","pubTime":"2025-05-23 16:11","pubTimestamp":1747987892,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc  said Thursday that it priced its underwritten public offering of about 2.2 million shares of its common stock at $9 per share for expected gross proceeds of about $20 million.The company also granted the underwriters a 30-day option to buy up to an additional 333,333 shares. The offering is expected to close on or about Tuesday.The company said it plans to use the net proceeds, along with its existing cash and cash equivalents and cash flows from operations, to advance its phase 2 clinical trial of F351 in the US, for research and development, manufacturing and scale-up, as well as for working capital and general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":75,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-09","symbol":"GYRE","fiscalQuarterEnding":"2025/03","expectedEps":0.03,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":0},{"market":"US","date":"2025-03-17","symbol":"GYRE","fiscalQuarterEnding":"2024/12","expectedEps":0.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"post","actualEps":0.01},{"date":"2025-02-18","symbol":"GYRE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739869200000,"name":null,"time":"Pre-Market","dateTimestamp":1739854800000,"actualEps":null},{"market":"US","date":"2024-11-13","symbol":"GYRE","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":0.02},{"market":"US","date":"2024-08-13","symbol":"GYRE","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741752000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2025-06-27","current":92.269436,"percent":0.887372,"low":-11548.718266,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"high":139.727206,"avg":-1155.549062,"sd":3094.591864,"marketCap":669045678},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789},{"date":"2025-04-25","current":70.645053,"twenty":-30.585076,"median":-12.780906,"eighty":-10.377285,"marketCap":853745471},{"date":"2025-05-02","current":72.449806,"twenty":-30.310846,"median":-12.626921,"eighty":-10.338636,"marketCap":875555902},{"date":"2025-05-09","current":73.535777,"twenty":-30.136978,"median":-12.473999,"eighty":-10.164715,"marketCap":888679866},{"date":"2025-05-16","current":132.923099,"twenty":-29.947887,"median":-12.417259,"eighty":-9.938068,"marketCap":963825388},{"date":"2025-05-23","current":136.20365,"twenty":-29.754799,"median":-12.327984,"eighty":-9.652614,"marketCap":987612669},{"date":"2025-05-30","current":117.840031,"twenty":-29.349619,"median":-12.308068,"eighty":-9.440044,"marketCap":854458067},{"date":"2025-06-06","current":99.64599,"twenty":-28.753768,"median":-12.251767,"eighty":50.257139,"marketCap":722533070},{"date":"2025-06-13","current":100.896253,"twenty":-28.630129,"median":-12.168656,"eighty":56.159719,"marketCap":731598729},{"date":"2025-06-20","current":104.146938,"twenty":-27.795567,"median":-12.087508,"eighty":59.335648,"marketCap":755169444},{"date":"2025-06-27","current":92.269436,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"marketCap":669045678}],"updateTime":1751107694703}}}